CardioDx Receives $35,000,000 Series D Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ec9a3583-3815-4d98-b080-cf9b62e828e2
Date
12/18/2014
Company Name
CardioDx
Mailing Address
600 Saginaw Drive Redwood City, CA 94063 USA
Company Description
Founded in 2004, CardioDx is a cardiovascular genomic diagnostics company. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
Website
http://www.cardiodx.com
Transaction Type
Venture Equity
Transaction Amount
$35,000,000
Transaction Round
Series D
Proceeds Purposes
The funds will enable CardioDx to broaden the commercial use of Corus CAD, the only clinically validated blood test that uses age, sex and gene expression to measure the likelihood of obstructive coronary artery disease in symptomatic patients, as well as to augment the company’s research efforts to improve healthcare quality and efficiency through the development of additional genomic tests for coronary artery disease.
M&A Terms
Venture Investor
Venture Investor